CARDIAC TISSUE MODELS AND METHODS OF USE THEREOF
- Technology Benefits
- Easily fabricated and can be mass produced A small number of cells required to form μHM
- Technology Application
- Research tool to study cardiomyocyte maturation, disease and cardiotoxicology in vitro Drug discovery
- Detailed Technology Description
- None
- Application No.
- WO2018067701
- Others
-
Publication
Miniaturized iPS-Cell-Derived Cardiac Muscles for Physiologically Relevant Drug Response Analyses
Additional Technologies by these Inventors
- Growth Factor Sequestering and Presenting Hydrogels
- Ethylsufonated Hyaluronic Acid Biopolymers
- Cardiac BioChip for Drug Screening
- Customizable Multi-Organ Biochip
- Universal Coating Compound
Tech ID/UC Case
27113/2017-043-0
Related Cases
2017-043-0
- *Abstract
-
Tissue engineering approaches have the potential to increase the physiologic relevance of human iPS-derived cells, such as cardiomyocytes (iPS-CM). However, forming Engineered Heart Muscle (EHM) typically requires >1 million cells per tissue. Existing miniaturization strategies involve complex approaches not amenable to mass production, limiting the ability to use EHM for iPS-based disease modeling and drug screening. Micro-scale cardiospheres are easily produced, but do not facilitate assembly of elongated muscle or direct force measurements.
UC Berkeley researchers have developed a 3D filamentous fiber matrix that combines features of EHM and cardiospheres: Micro-Heart Muscle (μHM) arrays, in which elongated muscle fibers are formed in an easily fabricated template, with as few as 2,000 iPS-CM per individual tissue. Within μHM, iPS-CM exhibit uniaxial contractility and alignment, robust sarcomere assembly, and reduced variability and hypersensitivity in drug responsiveness, compared to monolayers with the same cellular composition. μHM mounted onto standard force measurement apparatus exhibited a robust Frank-Starling response to external stretch, and a dose-dependent inotropic response to the β-adrenergic agonist isoproterenol.
- *IP Issue Date
- Apr 12, 2018
- *Principal Investigator
-
Name: Kevin Edward Healy
Department:
Name: Zhen Ma
Department:
- Country/Region
- USA
